These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8996559)

  • 1. Immunosuppressive activity of lymphocyte mitogenesis by breast cancer-associated p43.
    Reinerová M; Veselovská Z; Ausch C; Rosen HR
    Neoplasma; 1996; 43(6):363-6. PubMed ID: 8996559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of women with early breast cancer by analysis of p43-positive lymphocytes.
    Auerbach L; Hellan M; Stierer M; Rosen AC; Ausch C; Obwegeser R; Kubista E; Wolf G; Rosen HR; Panzer S
    Br J Cancer; 1999 May; 80(5-6):874-8. PubMed ID: 10360668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental isoferritin-associated p43 in pregnancy and breast cancer. Minireview.
    Rosen HR
    Neoplasma; 1996; 43(6):357-62. PubMed ID: 8996558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppression by breast cancer associated p43-effect of immunomodulators.
    Rosen HR; Ausch C; Reiner G; Reinerova M; Svec J; Tüchler H; Schiessel R; Moroz C
    Breast Cancer Res Treat; 1996; 41(2):171-6. PubMed ID: 8944335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells--a possible role for breast cancer-associated p43.
    Rosen HR; Ausch C; Reinerova M; Zaspin E; Renner K; Rosen AC; Schiessel R; Moroz C
    Cancer Lett; 1998 May; 127(1-2):129-34. PubMed ID: 9619868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p43 associated placental isoferritin (PLF) correlates inversely with cell growth in breast cancer cell lines MCF-7 and T47-D.
    Reinerová MH; Rosen HR; Veselovská Z; Stierer M; Svec J
    Neoplasma; 1993; 40(3):147-51. PubMed ID: 8350961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of lymphocyte mitogenesis by breast cancer-associated p43.
    Rosen HR; Ausch C; Reiner G; Reinerova M; Svec J; Tüchler H; Schiessel R; Moroz C
    Cancer Lett; 1994 Jul; 82(1):105-11. PubMed ID: 8033063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficient concanavalin-A-induced suppressor cell activity in women with untreated breast cancer.
    Gupta S; Cunningham-Rundles S
    J Clin Lab Immunol; 1982 Dec; 9(3):159-61. PubMed ID: 6220154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy.
    Sirota L; Kupfer B; Moroz C
    Clin Exp Immunol; 1989 Aug; 77(2):257-62. PubMed ID: 2528432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.
    Rosen HR; Moroz C; Reiner A; Reinerova M; Stierer M; Svec J; Schemper M; Jakesz R
    Breast Cancer Res Treat; 1992; 24(1):17-26. PubMed ID: 1463868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing differences in the concanavalin A-induced blastogenic responses of lymphocytes from breast cancer patients and controls by the use of alpha-methyl-D-mannoside.
    Distasio JA; Cheresh DA; Schilder RJ; Vogel CL; Silverman MA; Lopez DM
    J Natl Cancer Inst; 1982 Jan; 68(1):68-9. PubMed ID: 6948127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tumor-induced immunosuppression in breast cancer patients].
    Kharkevich DD; Polevaia EB; Kadagidze ZG
    Eksp Onkol; 1990; 12(5):53-6. PubMed ID: 2226260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes.
    Rohrer JW; Barsoum AL; Dyess DL; Tucker JA; Coggin JH
    J Immunol; 1999 Jun; 162(11):6880-92. PubMed ID: 10352310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lymphocyte subsets and response of breast cancer and benign mammary disease to PHA].
    Nakao S; Hayashida K; Hasegawa H; Ishii T; Eida K; Noguchi K
    Gan No Rinsho; 1987 Oct; 33(12):1453-8. PubMed ID: 3500331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of sera of breast cancer patients on NK cell activity].
    Konjević G; Spuzić I
    Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Suppressor activity induced by concanavalin A in peripheral blood lymphocytes of patients with solid malignant tumors].
    García MS; Barañao RI; Fernández O; Rumi LS
    Acta Physiol Lat Am; 1983; 33(1):15-20. PubMed ID: 6229133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cellular immunity in breast cancer patients].
    Spielmann M; Kitschke HJ; Tietje K
    Onkologie; 1982 Aug; 5 Suppl():42-5. PubMed ID: 6752790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
    Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of aromatase activity in breast tumours: the role of the immune system.
    Singh A; Purohit A; Duncan LJ; Mokbel K; Ghilchik MW; Reed MJ
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):185-92. PubMed ID: 9365189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular antitumor immune response in women with risk factors for breast cancer.
    Sanner T; Brennhovd I; Christensen I; Jørgensen O; Kvaløy S
    Cancer Res; 1979 Feb; 39(2 Pt 2):654-7. PubMed ID: 761231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.